Companies 89bio, Inc.
89bio (ETNB): executive pay, fiscal 2024
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me 89bio, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers40th pct.Of 15 peer CEOs
CEO pay, last three years
- $3,127,849FY2022
- $5,587,661FY2023
- $7,619,426FY2024
CEO total pay was $7,619,426 in fiscal 2024, up from $5,587,661 in fiscal 2023.
FY2024: salary $646,000 · bonus $0 · stock awards $1,996,000 · option awards $4,623,592
Executives and directors
Quoc Le-Nguyen · ExecutiveHank Mansbach · Chief Medical OfficerRohan Palekar · CEORyan Martins · CFOFrancis Sarena · COOCharles McWherter · Independent DirectorDerek DiRocco · Independent DirectorEdward Morrow Atkinson III · Independent DirectorKathleen D. LaPorte · Independent DirectorLota Zoth · Independent DirectorMartin Babler · Independent DirectorMichael Hayden · Independent DirectorSteven M. Altschuler · Chair of the Board
Frequently asked questions
Who was the highest-paid executive at 89bio, Inc. in fiscal 2024?
As disclosed, Rohan Palekar (Chief Executive Officer and Director) was the highest-paid executive at 89bio, Inc. in fiscal 2024, with total compensation of $7,619,426.
How does 89bio, Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, Rohan Palekar's total compensation ranked at the 40th percentile of 89bio, Inc.'s disclosed peer group.
What is 89bio, Inc.'s CEO-to-median employee pay ratio?
As disclosed, 89bio, Inc.'s CEO-to-median employee pay ratio was 19:1.
How much does 89bio, Inc. spend in total on board compensation for fiscal 2024?
As disclosed, 89bio, Inc. reported total board compensation of $440,903 for fiscal 2024.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Rohan Palekar | $646,000 | $0 | $1,996,000 | $4,623,592 | $337,535 | $0 | $16,299 | $7,619,426 |
| Chief Executive Officer and Director | ||||||||
| Hank Mansbach | 507,200 | 0 | 1,481,775 | 1,490,249 | 201,612 | 0 | 8,571 | 3,689,407 |
| Chief Medical Officer | ||||||||
| Quoc Le-Nguyen | 480,000 | 0 | 1,481,775 | 1,490,249 | 196,800 | 0 | 16,299 | 3,665,123 |
| Chief Technical Operations Officer | ||||||||
| Ryan Martins | 455,700 | 0 | 1,431,875 | 1,337,403 | 181,141 | 0 | 9,684 | 3,415,803 |
| Chief Financial Officer | ||||||||
| Francis Sarena | 204,545 | 0 | 209,750 | 2,191,175 | 79,858 | 0 | 6,616 | 2,691,944 |
| Chief Operating Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Rohan Palekar | $7,619,426 | $5,587,661 | $3,127,849 | ↑ +2,031,765 |
| Hank Mansbach | 3,689,407 | 2,542,387 | 1,535,311 | ↑ +1,147,020 |
| Quoc Le-Nguyen | 3,665,123 | 2,512,387 | 1,491,221 | ↑ +1,152,736 |
| Ryan Martins | 3,415,803 | — | — | — |
| Francis Sarena | 2,691,944 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our executive officer compensation program is designed to attract, retain and reward executive officers to promote our long-term success. In setting compensation levels and designing the elements of our program, we seek to establish overall compensation levels that are internally equitable and competitive with the talent market. We regularly review our executive officer compensation program with the goal of motivating our executive team to achieve our strategic goals and aligning their interests with those of our stockholders. In particular, we seek to: Align the base salary and target annual cash incentive compensation of our executive officers with market practices by targeting the 50th percentile of our executive compensation peer group; Align our equity-based compensation of our executive officers to target the 75th percentile of our executive compensation peer group; Focus the majority of our executive officers compensation on short-term and long-term incentive compensation; and Provide balanced incentives that motivate our executives to achieve our short-term and long-term goals without incentivizing executives to take excessive risks.
| CEO STI target (% of salary) | 55% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2024
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Ryan Martins | RSU | 2024-12-12 | — | — | 95,000 | — | $745,750 |
| Hank Mansbach | OPTION | 2024-02-01 | — | — | 195,000 | — | 1,490,249 |
| Quoc Le-Nguyen | RSU | 2024-02-01 | — | — | 48,750 | — | 486,525 |
| Ryan Martins | RSU | 2024-02-01 | — | — | 48,750 | — | 486,525 |
| Francis Sarena | OPTION | 2024-08-05 | — | — | 350,000 | — | 2,191,175 |
| Hank Mansbach | RSU | 2024-12-12 | — | — | 95,000 | — | 745,750 |
| Quoc Le-Nguyen | RSU | 2024-12-12 | — | — | 95,000 | — | 745,750 |
| Rohan Palekar | PSU | 2024-02-01 | — | 50,000 | — | 50,000 | 499,000 |
| Hank Mansbach | PSU | 2024-02-01 | — | 25,000 | — | 25,000 | 249,500 |
| Ryan Martins | PSU | 2024-02-01 | — | 20,000 | — | 20,000 | 199,600 |
| Quoc Le-Nguyen | PSU | 2024-02-01 | — | 25,000 | — | 25,000 | 249,500 |
| Francis Sarena | RSU | 2024-08-05 | — | — | 25,000 | — | 209,750 |
| Hank Mansbach | RSU | 2024-02-01 | — | — | 48,750 | — | 486,525 |
| Ryan Martins | OPTION | 2024-02-01 | — | — | 175,000 | — | 1,337,403 |
| Rohan Palekar | RSU | 2024-02-01 | — | — | 150,000 | — | 1,497,000 |
| Quoc Le-Nguyen | OPTION | 2024-02-01 | — | — | 195,000 | — | 1,490,249 |
| Rohan Palekar | OPTION | 2024-02-01 | — | — | 605,000 | — | 4,623,592 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Ryan Martins | $1,232,275 | $199,600 | $1,337,403 | 7.2% |
| Hank Mansbach | 1,232,275 | 249,500 | 1,490,249 | 8.4% |
| Quoc Le-Nguyen | 1,232,275 | 249,500 | 1,490,249 | 8.4% |
| Francis Sarena | 209,750 | 0 | 2,191,175 | 0.0% |
| Rohan Palekar | 1,497,000 | 499,000 | 4,623,592 | 7.5% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2024
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Ryan Martins | RSU | 2,178 | — | $17,032 |
| Hank Mansbach | RSU | 2,932 | — | 22,928 |
| Quoc Le-Nguyen | RSU | 2,932 | — | 22,928 |
| Ryan Martins | Option | 3,594 | 23.01 | — |
| Hank Mansbach | Option | 4,219 | 23.01 | — |
| Quoc Le-Nguyen | Option | 4,219 | 23.01 | — |
| Rohan Palekar | RSU | 9,079 | — | 70,998 |
| Rohan Palekar | Option | 12,735 | 23.01 | — |
| Ryan Martins | PSU | 15,000 | — | 117,300 |
| Ryan Martins | Option | 16,250 | 4.44 | — |
| Ryan Martins | RSU | 20,000 | — | 156,400 |
| Ryan Martins | PSU | 20,000 | — | 156,400 |
| Hank Mansbach | RSU | 20,000 | — | 156,400 |
| Quoc Le-Nguyen | RSU | 20,000 | — | 156,400 |
| Hank Mansbach | Option | 21,875 | 4.44 | — |
| Quoc Le-Nguyen | Option | 21,875 | 4.44 | — |
| Hank Mansbach | PSU | 25,000 | — | 195,500 |
| Quoc Le-Nguyen | PSU | 25,000 | — | 195,500 |
| Francis Sarena | RSU | 25,000 | — | 195,500 |
| Ryan Martins | RSU | 40,624 | — | 317,680 |
| Hank Mansbach | RSU | 40,624 | — | 317,680 |
| Quoc Le-Nguyen | RSU | 40,624 | — | 317,680 |
| Rohan Palekar | RSU | 50,000 | — | 391,000 |
| Rohan Palekar | PSU | 50,000 | — | 391,000 |
| Ryan Martins | Option | 61,875 | 14.7 | — |
| Hank Mansbach | Option | 67,500 | 14.7 | — |
| Quoc Le-Nguyen | Option | 67,500 | 14.7 | — |
| Rohan Palekar | Option | 68,750 | 4.44 | — |
| Rohan Palekar | PSU | 75,000 | — | 586,500 |
| Ryan Martins | RSU | 95,000 | — | 742,900 |
| Hank Mansbach | RSU | 95,000 | — | 742,900 |
| Quoc Le-Nguyen | RSU | 95,000 | — | 742,900 |
| Rohan Palekar | RSU | 124,955 | — | 977,461 |
| Rohan Palekar | Option | 168,750 | 14.7 | — |
| Ryan Martins | Option | 175,000 | 9.98 | — |
| Hank Mansbach | Option | 195,000 | 9.98 | — |
| Quoc Le-Nguyen | Option | 195,000 | 9.98 | — |
| Francis Sarena | Option | 350,000 | 8.39 | — |
| Rohan Palekar | Option | 605,000 | 9.98 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Martin BablerIndependent · Compensation · Science · Newly elected | $33,929 | $0 | $455,316 | — | $0 | $489,245 |
| Charles McWherterIndependent · Nominating · Science · Newly elected | 18,604 | 0 | 421,642 | — | 0 | 440,246 |
| Steven M. AltschulerIndependent · Board Chair · Audit · Compensation | 87,500 | 0 | 332,467 | — | 0 | 419,967 |
| Lota ZothIndependent · Audit (Chair) · Compensation | 67,500 | 0 | 332,467 | — | 0 | 399,967 |
| Kathleen D. LaPorteIndependent · Compensation (Chair) · Nominating | 65,870 | 0 | 332,467 | — | 0 | 398,337 |
| Michael HaydenIndependent · Compensation · Science (Chair) | 60,000 | 0 | 332,467 | — | 0 | 392,467 |
| Edward Morrow Atkinson IIIIndependent · Compensation (Chair) · Nominating | 56,250 | 0 | 332,467 | — | 0 | 388,717 |
| Derek DiRoccoIndependent · Nominating · Science | 51,250 | 0 | 332,467 | — | 0 | 383,717 |
| Rohan PalekarEmployee director | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $332,467 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $440,903 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $440,903 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names 89bio as a peer
Companies that benchmark against ETNB
4 companies name ETNB as a compensation peer
- Altimmune, Inc.ALTFY2025
- Atea Pharmaceuticals, Inc.AVIRFY2025
- Disc Medicine, Inc.IRONFY2025
- LIGAND PHARMACEUTICALS INCLGNDFY2025
Each company listed discloses ETNB in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ETNB in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2024
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
IMVT ImmunovantAKRO Akero TherapeuticsDNLI Denali TherapeuticsKALV KalVista PharmaceuticalsPLRX Pliant TherapeuticsRAPT RAPT TherapeuticsTERN Terns PharmaceuticalsVTYX Ventyx BiosciencesVERA Vera TherapeuticsMDGL Madrigal PharmaceuticalsMIRM Mirum PharmaceuticalsVKTX Viking TherapeuticsPTGX Protagonist TherapeuticsARWR Arrowhead PharmaceuticalsCYTK Cytokinetics
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Viking Therapeutics | 2025 | Brian Lian | $672,000 | $17,756,817 | $2,468,016 | $373,000 | $21,269,833 |
| 2 | Immunovant | 2026 | Eric Venker | 636,618 | 0 | 19,010,639 | 0 | 20,158,767 |
| 3 | Madrigal Pharmaceuticals | 2025 | Bill Sibold | 918,531 | 12,297,850 | 4,537,146 | 1,438,814 | 19,206,341 |
| 4 | Protagonist Therapeutics | 2025 | Dinesh Patel | 715,500 | 5,839,204 | 5,618,010 | 686,880 | 12,871,506 |
| 5 | Cytokinetics | 2025 | Robert Blum | 853,069 | 5,150,019 | 5,095,918 | 772,715 | 11,881,456 |
| 6 | Akero Therapeutics | 2024 | Andrew Cheng | 686,000 | 2,879,155 | 6,489,100 | 411,600 | 10,465,855 |
| 7 | Mirum Pharmaceuticals | 2025 | Christopher Peetz | 755,000 | 3,683,904 | 4,931,320 | 1,057,000 | 10,441,224 |
| 8 | Arrowhead Pharmaceuticals | 2025 | Christopher Anzalone | 981,046 | 6,810,292 | 0 | 1,236,000 | 9,029,861 |
| 9 | Terns Pharmaceuticals | 2024 | Amy Burroughs | 563,701 | 807,750 | 6,476,968 | 375,000 | 8,240,502 |
| 10 | 89bio, Inc. | 2024 | Rohan Palekar | 646,000 | 1,996,000 | 4,623,592 | 337,535 | 7,619,426 |
| 11 | Vera Therapeutics | 2025 | Marshall Fordyce | 660,000 | 2,356,285 | 3,415,725 | 554,400 | 6,986,410 |
| 12 | Rapt Therapeutics | 2024 | Brian Wong | 630,000 | 0 | 5,927,297 | 416,000 | 6,979,539 |
| 13 | Pliant Therapeutics | 2025 | Bernard Coulie | 682,000 | 1,810,250 | 2,713,750 | 204,600 | 5,462,901 |
| 14 | KalVista Pharmaceuticals | 2025 | Benjamin Palleiko | 477,202 | 3,731,160 | 0 | 0 | 5,094,999 |
| 15 | Denali Therapeutics | 2025 | Ryan Watts | 718,000 | 1,151,867 | 2,180,003 | 0 | 4,751,515 |
| 16 | Ventyx Biosciences | 2024 | Raju Mohan | 621,920 | 0 | 303,800 | 342,045 | 1,283,015 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| 89bio, Inc. | 95% | not disclosed | No | Aon |
| Akero Therapeutics | 100% | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| Arrowhead Pharmaceuticals | 125% | PRSU 70 · RSU 30 | not disclosed | Compensia |
| Cytokinetics | 120% | RSU 50 · Options 50 | not disclosed | Aon Human Capital Solutions |
| Denali Therapeutics | 145% | not disclosed | not disclosed | Alpine Rewards |
| Immunovant | 110% | not disclosed | No | Compensia |
| KalVista Pharmaceuticals | not disclosed | not disclosed | No | Aon |
| Madrigal Pharmaceuticals | not disclosed | PSU 33.33 · RSU 33.33 · Option 33.33 | Yes — Relative TSR vs Nasdaq Biotechnology Index | Compensia, Inc. |
| Mirum Pharmaceuticals | 200% | Option 47.2 · PSU 17.6 · RSU 17.6 | No | Alpine Rewards |
| Pliant Therapeutics | not disclosed | Option 66.67 · RSU 33.33 | not disclosed | Pearl Meyer; Alpine Rewards |
| Protagonist Therapeutics | 160% | Options 50 · RSU 50 | not disclosed | Aon Human Capital Solutions |
| Rapt Therapeutics | 120% | Option 100 | not disclosed | Aon plc/Radford |
| Terns Pharmaceuticals | 120% | not disclosed | No | Alpine Rewards |
| Ventyx Biosciences | not disclosed | not disclosed | not disclosed | AON/Radford |
| Vera Therapeutics | not disclosed | RSU 50 · Options 50 | not disclosed | Alpine Rewards |
| Viking Therapeutics | not disclosed | not disclosed | No | Aon |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
No say-on-pay vote is on file for this company.
CEO pay ratio
| Ratio (CEO : median employee) | 19 : 1 |
|---|---|
| CEO total compensation | $7,619,426 |
| Median employee compensation | $396,532 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Quoc Le-Nguyen | See Remarks | 2025-04-15 | D | 15,329 | $6 | $91,208 | Common, open-market sale | Form 4 ↗ |
| Quoc Le-Nguyen | See Remarks | 2025-06-12 | D | 8,498 | 10 | 81,751 | Common | Form 4 ↗ |
| Hank Mansbach | Chief Medical Officer | 2025-06-12 | D | 8,498 | 10 | 81,751 | Common | Form 4 ↗ |
| Ryan Martins | Chief Financial Officer | 2025-06-12 | D | 8,498 | 10 | 81,751 | Common | Form 4 ↗ |
| Quoc Le-Nguyen | See Remarks | 2025-06-12 | D | 534 | 10 | 5,137 | Common | Form 4 ↗ |
| Quoc Le-Nguyen | See Remarks | 2025-07-15 | D | 10,461 | 11 | 115,280 | Common, open-market sale | Form 4 ↗ |
| Ryan Martins | Chief Financial Officer | 2025-08-01 | D | 7,680 | 9 | 70,349 | Common | Form 4 ↗ |
| Francis Sarena | Chief Operating Officer | 2025-08-01 | D | 3,206 | 9 | 29,367 | Common | Form 4 ↗ |
| Hank Mansbach | Chief Medical Officer | 2025-08-01 | D | 7,680 | 9 | 70,349 | Common | Form 4 ↗ |
| Rohan Palekar | Director | 2025-08-01 | D | 55,836 | 9 | 511,458 | Common | Form 4 ↗ |
| Quoc Le-Nguyen | See Remarks | 2025-08-01 | D | 522 | 9 | 4,782 | Common | Form 4 ↗ |
| Quoc Le-Nguyen | See Remarks | 2025-08-01 | D | 7,680 | 9 | 70,349 | Common | Form 4 ↗ |
| Francis Sarena | Chief Operating Officer | 2025-08-05 | D | 2,979 | 10 | 28,867 | Common | Form 4 ↗ |
| Ryan Martins | Chief Financial Officer | 2025-10-22 | D | 3,898 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ryan Martins | Chief Financial Officer | 2025-10-22 | D | 76,901 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ryan Martins | Chief Financial Officer | 2025-10-22 | A | 3,898 | 4 | 17,307 | Common | Form 4 ↗ |
| Ryan Martins | Chief Financial Officer | 2025-10-22 | A | 76,901 | 3 | 239,162 | Common | Form 4 ↗ |
| Hank Mansbach | Chief Medical Officer | 2025-10-30 | D | 320,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Hank Mansbach | Chief Medical Officer | 2025-10-30 | D | 67,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Hank Mansbach | Chief Medical Officer | 2025-10-30 | D | 45,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Hank Mansbach | Chief Medical Officer | 2025-10-30 | D | 98,204 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Hank Mansbach | Chief Medical Officer | 2025-10-30 | D | 352,656 | — | — | Common | Form 4 ↗ |
| Francis Sarena | Chief Operating Officer | 2025-10-30 | D | 215,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Derek DiRocco | Director | 2025-10-30 | D | 7,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Martin Babler | Director | 2025-10-30 | D | 56,400 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Martin Babler | Director | 2025-10-30 | D | 67,700 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Quoc Le-Nguyen | See Remarks | 2025-10-30 | D | 26,400 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Quoc Le-Nguyen | See Remarks | 2025-10-30 | D | 320,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Quoc Le-Nguyen | See Remarks | 2025-10-30 | D | 50,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Quoc Le-Nguyen | See Remarks | 2025-10-30 | D | 3,312 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Quoc Le-Nguyen | See Remarks | 2025-10-30 | D | 4,063 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Quoc Le-Nguyen | See Remarks | 2025-10-30 | A | 50,000 | 0 | 0 | Common | Form 4 ↗ |
| Lota Zoth | Director | 2025-10-30 | D | 56,400 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lota Zoth | Director | 2025-10-30 | D | 45,150 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lota Zoth | Director | 2025-10-30 | D | 27,400 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lota Zoth | Director | 2025-10-30 | D | 12,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Edward Morrow Atkinson III | Director | 2025-10-30 | D | 56,400 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Edward Morrow Atkinson III | Director | 2025-10-30 | D | 45,150 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Charles McWherter | Director | 2025-10-30 | D | 25,000 | — | — | Common | Form 4 ↗ |
| Rohan Palekar | Director | 2025-10-30 | D | 848,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Rohan Palekar | Director | 2025-10-30 | D | 300,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Rohan Palekar | Director | 2025-10-30 | D | 220,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Rohan Palekar | Director | 2025-10-30 | D | 203,750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Rohan Palekar | Director | 2025-10-30 | D | 170,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Rohan Palekar | Director | 2025-10-30 | D | 120,231 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven M. Altschuler | Director | 2025-10-30 | D | 56,400 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven M. Altschuler | Director | 2025-10-30 | D | 27,400 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven M. Altschuler | Director | 2025-10-30 | D | 25,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven M. Altschuler | Director | 2025-10-30 | D | 7,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven M. Altschuler | Director | 2025-10-30 | D | 40,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ryan Martins | Chief Financial Officer | 2025-10-30 | D | 48,102 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ryan Martins | Chief Financial Officer | 2025-10-30 | D | 57,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ryan Martins | Chief Financial Officer | 2025-10-30 | D | 47,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ryan Martins | Chief Financial Officer | 2025-10-30 | D | 374,295 | — | — | Common | Form 4 ↗ |
| Ryan Martins | Chief Financial Officer | 2025-10-30 | A | 35,000 | 0 | 0 | Common | Form 4 ↗ |
| Kathleen D. LaPorte | Director | 2025-10-30 | D | 25,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| RA CAPITAL MANAGEMENT, L.P. | Director | 2025-10-30 | D | 45,150 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| RA CAPITAL MANAGEMENT, L.P. | Director | 2025-10-30 | D | 12,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| RA CAPITAL MANAGEMENT, L.P. | Director | 2025-10-30 | D | 7,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| RA CAPITAL MANAGEMENT, L.P. | Director | 2025-10-30 | D | 7,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| RA CAPITAL MANAGEMENT, L.P. | Director | 2025-10-30 | D | 4,331,081 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| RA CAPITAL MANAGEMENT, L.P. | Director | 2025-10-30 | D | 335,364 | — | — | Common | Form 4 ↗ |
| Michael Hayden | Director | 2025-10-30 | D | 45,150 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Hayden | Director | 2025-10-30 | D | 27,400 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Hayden | Director | 2025-10-30 | D | 25,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Hayden | Director | 2025-10-30 | D | 12,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Hayden | Director | 2025-10-30 | D | 7,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Hayden | Director | 2025-10-30 | D | 27,647 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Hayden | Director | 2025-10-30 | D | 61,538 | — | — | Common | Form 4 ↗ |
| Michael Hayden | Director | 2025-10-30 | D | 103,978 | — | — | Common | Form 4 ↗ |
| Michael Hayden | Director | 2025-10-30 | D | 80,904 | — | — | Common | Form 4 ↗ |
| Kathleen D. LaPorte | Director | 2025-10-30 | D | 45,150 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Hank Mansbach | Chief Medical Officer | 2025-10-30 | D | 120,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Hank Mansbach | Chief Medical Officer | 2025-10-30 | D | 39,037 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Quoc Le-Nguyen | See Remarks | 2025-10-30 | D | 70,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Quoc Le-Nguyen | See Remarks | 2025-10-30 | D | 67,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Quoc Le-Nguyen | See Remarks | 2025-10-30 | D | 13,694 | — | — | Common | Form 4 ↗ |
| Lota Zoth | Director | 2025-10-30 | D | 25,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Edward Morrow Atkinson III | Director | 2025-10-30 | D | 27,400 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Rohan Palekar | Director | 2025-10-30 | D | 934,273 | — | — | Common | Form 4 ↗ |
| Ryan Martins | Chief Financial Officer | 2025-10-30 | D | 175,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Hayden | Director | 2025-10-30 | D | 7,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kathleen D. LaPorte | Director | 2025-10-30 | D | 56,400 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kathleen D. LaPorte | Director | 2025-10-30 | D | 27,400 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kathleen D. LaPorte | Director | 2025-10-30 | D | 12,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| RA CAPITAL MANAGEMENT, L.P. | Director | 2025-10-30 | D | 56,400 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| RA CAPITAL MANAGEMENT, L.P. | Director | 2025-10-30 | D | 27,400 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Hank Mansbach | Chief Medical Officer | 2025-10-30 | D | 195,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Hank Mansbach | Chief Medical Officer | 2025-10-30 | A | 50,000 | 0 | 0 | Common | Form 4 ↗ |
| Francis Sarena | Chief Operating Officer | 2025-10-30 | D | 350,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francis Sarena | Chief Operating Officer | 2025-10-30 | D | 75,310 | — | — | Common | Form 4 ↗ |
| Derek DiRocco | Director | 2025-10-30 | D | 45,150 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Derek DiRocco | Director | 2025-10-30 | D | 27,400 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Rohan Palekar | Director | 2025-10-30 | D | 132,242 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ryan Martins | Chief Financial Officer | 2025-10-30 | D | 110,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Hayden | Director | 2025-10-30 | D | 2,933 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| RA CAPITAL MANAGEMENT, L.P. | Director | 2025-10-30 | D | 25,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Hayden | Director | 2025-10-30 | D | 56,400 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| RA CAPITAL MANAGEMENT, L.P. | Director | 2025-10-30 | D | 19,554,319 | — | — | Common | Form 4 ↗ |
| Hank Mansbach | Chief Medical Officer | 2025-10-30 | D | 70,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Quoc Le-Nguyen | See Remarks | 2025-10-30 | D | 17,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Quoc Le-Nguyen | See Remarks | 2025-10-30 | D | 195,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Quoc Le-Nguyen | See Remarks | 2025-10-30 | D | 120,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Quoc Le-Nguyen | See Remarks | 2025-10-30 | D | 351,684 | — | — | Common | Form 4 ↗ |
| Lota Zoth | Director | 2025-10-30 | D | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Rohan Palekar | Director | 2025-10-30 | A | 125,000 | 0 | 0 | Common | Form 4 ↗ |
| Ryan Martins | Chief Financial Officer | 2025-10-30 | D | 300,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Charles McWherter | Director | 2025-10-30 | D | 67,700 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Derek DiRocco | Director | 2025-10-30 | D | 25,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Derek DiRocco | Director | 2025-10-30 | D | 7,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Rohan Palekar | Director | 2025-10-30 | D | 605,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Derek DiRocco | Director | 2025-10-30 | D | 12,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Derek DiRocco | Director | 2025-10-30 | D | 56,400 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven M. Altschuler | Director | 2025-10-30 | D | 45,150 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven M. Altschuler | Director | 2025-10-30 | D | 12,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Hayden | Director | 2025-10-30 | D | 22,730 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Charles McWherter | Director | 2025-10-30 | D | 56,400 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Edward Morrow Atkinson III | Director | 2025-10-30 | D | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (169 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Rohan Palekar. DEF 14A, filed 2025-04-15. Section “2024 Summary Compensation Table” · page 36. As printed: 7,619,426. View filing ↗
- Section 01, Hank Mansbach. DEF 14A, filed 2025-04-15. Section “2024 Summary Compensation Table”. As printed: 3,689,407. View filing ↗
- Section 01, Quoc Le-Nguyen. DEF 14A, filed 2025-04-15. Section “2024 Summary Compensation Table”. As printed: 3,665,123. View filing ↗
- Section 01, Ryan Martins. DEF 14A, filed 2025-04-15. Section “2024 Summary Compensation Table”. As printed: 3,415,803. View filing ↗
- Section 01, Francis Sarena. DEF 14A, filed 2025-04-15. Section “2024 Summary Compensation Table”. As printed: 2,691,944. View filing ↗
- Section 03, Ryan Martins RSU. DEF 14A, filed 2025-04-15. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Hank Mansbach OPTION. DEF 14A, filed 2025-04-15. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Quoc Le-Nguyen RSU. DEF 14A, filed 2025-04-15. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Ryan Martins RSU. DEF 14A, filed 2025-04-15. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Francis Sarena OPTION. DEF 14A, filed 2025-04-15. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Hank Mansbach RSU. DEF 14A, filed 2025-04-15. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Quoc Le-Nguyen RSU. DEF 14A, filed 2025-04-15. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Rohan Palekar PSU. DEF 14A, filed 2025-04-15. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Hank Mansbach PSU. DEF 14A, filed 2025-04-15. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Ryan Martins PSU. DEF 14A, filed 2025-04-15. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Quoc Le-Nguyen PSU. DEF 14A, filed 2025-04-15. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Francis Sarena RSU. DEF 14A, filed 2025-04-15. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Hank Mansbach RSU. DEF 14A, filed 2025-04-15. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Ryan Martins OPTION. DEF 14A, filed 2025-04-15. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Rohan Palekar RSU. DEF 14A, filed 2025-04-15. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Quoc Le-Nguyen OPTION. DEF 14A, filed 2025-04-15. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Rohan Palekar OPTION. DEF 14A, filed 2025-04-15. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2025-04-15. Section “CEO Pay Ratio”. As printed: 19 : 1. View filing ↗
- Section 08, Martin Babler. DEF 14A, filed 2025-04-15. Section “Director Compensation”. As printed: 489,245. View filing ↗
- Section 08, Charles McWherter. DEF 14A, filed 2025-04-15. Section “Director Compensation”. As printed: 440,246. View filing ↗
- Section 08, Steven M. Altschuler. DEF 14A, filed 2025-04-15. Section “Director Compensation”. As printed: 419,967. View filing ↗
- Section 08, Lota Zoth. DEF 14A, filed 2025-04-15. Section “Director Compensation”. As printed: 399,967. View filing ↗
- Section 08, Kathleen D. LaPorte. DEF 14A, filed 2025-04-15. Section “Director Compensation”. As printed: 398,337. View filing ↗
- Section 08, Michael Hayden. DEF 14A, filed 2025-04-15. Section “Director Compensation”. As printed: 392,467. View filing ↗
- Section 08, Edward Morrow Atkinson III. DEF 14A, filed 2025-04-15. Section “Director Compensation”. As printed: 388,717. View filing ↗
- Section 08, Derek DiRocco. DEF 14A, filed 2025-04-15. Section “Director Compensation”. As printed: 383,717. View filing ↗
- Section 08, Rohan Palekar. DEF 14A, filed 2025-04-15. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Quoc Le-Nguyen 2025-04-15. Form 4, filed 2025-04-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Quoc Le-Nguyen 2025-06-12. Form 4, filed 2025-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hank Mansbach 2025-06-12. Form 4, filed 2025-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ryan Martins 2025-06-12. Form 4, filed 2025-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Quoc Le-Nguyen 2025-06-12. Form 4, filed 2025-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Quoc Le-Nguyen 2025-07-15. Form 4, filed 2025-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ryan Martins 2025-08-01. Form 4, filed 2025-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Francis Sarena 2025-08-01. Form 4, filed 2025-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hank Mansbach 2025-08-01. Form 4, filed 2025-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rohan Palekar 2025-08-01. Form 4, filed 2025-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Quoc Le-Nguyen 2025-08-01. Form 4, filed 2025-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Quoc Le-Nguyen 2025-08-01. Form 4, filed 2025-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Francis Sarena 2025-08-05. Form 4, filed 2025-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ryan Martins 2025-10-22. Form 4, filed 2025-10-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ryan Martins 2025-10-22. Form 4, filed 2025-10-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ryan Martins 2025-10-22. Form 4, filed 2025-10-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ryan Martins 2025-10-22. Form 4, filed 2025-10-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hank Mansbach 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hank Mansbach 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hank Mansbach 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hank Mansbach 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hank Mansbach 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Francis Sarena 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Derek DiRocco 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Martin Babler 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Martin Babler 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Quoc Le-Nguyen 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Quoc Le-Nguyen 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Quoc Le-Nguyen 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Quoc Le-Nguyen 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Quoc Le-Nguyen 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Quoc Le-Nguyen 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lota Zoth 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lota Zoth 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lota Zoth 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lota Zoth 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Edward Morrow Atkinson III 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Edward Morrow Atkinson III 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles McWherter 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rohan Palekar 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rohan Palekar 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rohan Palekar 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rohan Palekar 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rohan Palekar 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rohan Palekar 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven M. Altschuler 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven M. Altschuler 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven M. Altschuler 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven M. Altschuler 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven M. Altschuler 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ryan Martins 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ryan Martins 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ryan Martins 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ryan Martins 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ryan Martins 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kathleen D. LaPorte 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, RA CAPITAL MANAGEMENT, L.P. 2025-10-30. Form 4, filed 2025-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, RA CAPITAL MANAGEMENT, L.P. 2025-10-30. Form 4, filed 2025-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, RA CAPITAL MANAGEMENT, L.P. 2025-10-30. Form 4, filed 2025-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, RA CAPITAL MANAGEMENT, L.P. 2025-10-30. Form 4, filed 2025-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, RA CAPITAL MANAGEMENT, L.P. 2025-10-30. Form 4, filed 2025-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, RA CAPITAL MANAGEMENT, L.P. 2025-10-30. Form 4, filed 2025-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Hayden 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Hayden 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Hayden 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Hayden 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Hayden 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Hayden 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Hayden 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Hayden 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Hayden 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kathleen D. LaPorte 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hank Mansbach 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hank Mansbach 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Quoc Le-Nguyen 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Quoc Le-Nguyen 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Quoc Le-Nguyen 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lota Zoth 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Edward Morrow Atkinson III 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rohan Palekar 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ryan Martins 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Hayden 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kathleen D. LaPorte 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kathleen D. LaPorte 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kathleen D. LaPorte 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, RA CAPITAL MANAGEMENT, L.P. 2025-10-30. Form 4, filed 2025-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, RA CAPITAL MANAGEMENT, L.P. 2025-10-30. Form 4, filed 2025-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hank Mansbach 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hank Mansbach 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Francis Sarena 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Francis Sarena 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Derek DiRocco 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Derek DiRocco 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rohan Palekar 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ryan Martins 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Hayden 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, RA CAPITAL MANAGEMENT, L.P. 2025-10-30. Form 4, filed 2025-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Hayden 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, RA CAPITAL MANAGEMENT, L.P. 2025-10-30. Form 4, filed 2025-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hank Mansbach 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Quoc Le-Nguyen 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Quoc Le-Nguyen 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Quoc Le-Nguyen 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Quoc Le-Nguyen 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lota Zoth 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rohan Palekar 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ryan Martins 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles McWherter 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Derek DiRocco 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Derek DiRocco 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rohan Palekar 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Derek DiRocco 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Derek DiRocco 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven M. Altschuler 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven M. Altschuler 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Hayden 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles McWherter 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Edward Morrow Atkinson III 2025-10-30. Form 4, filed 2025-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 440,903 + equity 0 + all other 0 = 440,903, summed across the director compensation table rows.
- Viking Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-01. CEO total compensation as printed in Viking Therapeutics's own proxy. As printed: 21,269,833. View filing ↗
- Immunovant, Section 10b CEO total. DEF 14A, filed 2026-07-22. CEO total compensation as printed in Immunovant's own proxy. As printed: 20,158,767. View filing ↗
- Madrigal Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Madrigal Pharmaceuticals's own proxy. As printed: 19,206,341. View filing ↗
- Protagonist Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Protagonist Therapeutics's own proxy. As printed: 12,871,506. View filing ↗
- Cytokinetics, Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Cytokinetics's own proxy. As printed: 11,881,456. View filing ↗
- Akero Therapeutics, Section 10b CEO total. DEF 14A, filed 2025-04-28. CEO total compensation as printed in Akero Therapeutics's own proxy. As printed: 10,465,855. View filing ↗
- Mirum Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Mirum Pharmaceuticals's own proxy. As printed: 10,441,224. View filing ↗
- Arrowhead Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-01-27. CEO total compensation as printed in Arrowhead Pharmaceuticals's own proxy. As printed: 9,029,861. View filing ↗
- Terns Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2025-04-29. CEO total compensation as printed in Terns Pharmaceuticals's own proxy. As printed: 8,240,502. View filing ↗
- 89bio, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2025-04-15. CEO total compensation as printed in 89bio, Inc.'s own proxy. As printed: 7,619,426. View filing ↗
- Vera Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-09. CEO total compensation as printed in Vera Therapeutics's own proxy. As printed: 6,986,410. View filing ↗
- Rapt Therapeutics, Section 10b CEO total. DEF 14A, filed 2025-04-14. CEO total compensation as printed in Rapt Therapeutics's own proxy. As printed: 6,979,539. View filing ↗
- Pliant Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Pliant Therapeutics's own proxy. As printed: 5,462,901. View filing ↗
- KalVista Pharmaceuticals, Section 10b CEO total. 10-KT/A, filed 2026-04-30. CEO total compensation as printed in KalVista Pharmaceuticals's own proxy. As printed: 5,094,999. View filing ↗
- Denali Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Denali Therapeutics's own proxy. As printed: 4,751,515. View filing ↗
- Ventyx Biosciences, Section 10b CEO total. DEF 14A, filed 2025-04-23. CEO total compensation as printed in Ventyx Biosciences's own proxy. As printed: 1,283,015. View filing ↗